Drug profile · INN
tofersen
QALSODY
tofersen (QALSODY) is a sod1 mrna inhibitor. Route of administration: intrathecal. Current US regulatory status: approved.
FDA: approved EMA: approved PMDA: approved Nervous system (N07) N07XX22
US status approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — tofersen
- US status
- approved
- Class
- Nervous system (N07)
- Route
- INTRATHECAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
tofersen (QALSODY) is a sod1 mrna inhibitor. Route of administration: intrathecal. Current US regulatory status: approved.
Key facts
INN tofersen
Brand QALSODY
Mechanism SOD1 mRNA inhibitor
Target SOD1 mRNA
Therapeutic class Nervous system (N07)
Route INTRATHECAL
Formulation SOLUTION
ATC code N07XX22
Mechanism of action
SOD1 mRNA inhibitor
Primary target: SOD1 mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tofersen?
tofersen (QALSODY) is a sod1 mrna inhibitor. Route of administration: intrathecal. Current US regulatory status: approved.
What is the brand name for tofersen?
QALSODY is a marketed brand name for tofersen. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tofersen?
tofersen has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.